Skip to content
Clinical Trials – home

Hospital Santa Caterina Ias

Verified siteinfo

Spain Calle Del Doctor Castany S/N, 17190 Salt, Spain

  • 4 trials recruiting
  • Multiple sclerosis · Multiple sclerosis relapse · Primary progressive multiple sclerosis
  • Adult patients

About Specializations

Hospital Santa Caterina Ias in Salt, Spain specialises in clinical trials of conditions such as Multiple sclerosis, Multiple sclerosis relapse, Primary progressive multiple sclerosis, Relapsing multiple sclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Maternal Health and Pregnancy

The medical center is at the forefront of research in maternal health, focusing on improving the quality of life for pregnant women experiencing nausea and vomiting of pregnancy (NVP). Through innovative clinical trials, the center evaluates the efficacy of novel therapeutic combinations, such as the fixed-dose combination of doxylamine and pyridoxine, to alleviate symptoms and enhance well-being during pregnancy.

  • Nausea and Vomiting of Pregnancy (NVP)
  • Quality of Life Improvements
  • Modified-Release Therapeutics

By advancing treatment options for NVP, the center contributes significantly to the field of obstetrics, ensuring better health outcomes for both mothers and their unborn children.

Neurology and Multiple Sclerosis

Specializing in neurology, the medical center conducts pivotal research on relapsing multiple sclerosis (RMS). The institution is dedicated to evaluating the efficacy and tolerability of advanced treatments, such as ofatumumab, compared to first-line disease-modifying therapies (DMTs). This research aims to provide newly diagnosed patients with more effective and personalized treatment options.

  • Relapsing Multiple Sclerosis (RMS)
  • Advanced Disease-Modifying Therapies
  • Patient-Centric Treatment Approaches

Through its commitment to cutting-edge research, the center plays a crucial role in enhancing therapeutic strategies for RMS, ultimately improving patient outcomes and quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle Del Doctor Castany S/N17190 SaltSpain
Recruiting now
4 trials
Conditions studied
8
Partner status
Verified site

More sites in SaltSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

13 clinical trials

Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Novartis Pharma AG

Dermatitis acneiform

Not recruiting

A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Hoth Therapeutics Inc.

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Morning sickness

Not recruiting

Study on Doxylamine and Pyridoxine for Pregnant Women with Nausea and Vomiting

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Doxylamine Hydrogen Succinate
  • Sponsor:Itf Research Pharma S.L.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.